SPDR S&P Biotech (XBI) 51.94 $XBI Last Week's B
Post# of 273323
Posted On: 03/06/2016 3:50:49 AM
SPDR S&P Biotech (XBI) 51.94 $XBI
Last Week's Best Healthcare ETF
Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 05, 1:00PM CST
IMAGE BY TBIT VIA PIXABAY. It was another good week to be a healthcare-focused investor. as many of the most popular exchange-traded funds that concentrate on the sector continued to recover from their dreadful start to the year. Several of these...
MDVN: 40.44 (+2.24), ZIOP: 8.95 (-0.64), XBI: 51.94 (+0.22)
So Many Topics, So Few Columns
at The Street - Sat Mar 05, 11:00AM CST
In response to reader input, here's what to look for from me.
XBI: 51.94 (+0.22), IBB: 263.13 (-1.11), BAC: 13.54 (+0.04), GDX: 19.71 (-0.11)
Trader's Notebook: Is It Biotech's Turn to Outperform?
at The Street - Fri Mar 04, 8:00AM CST
The biotechnology sector has lagged horribly.
VALE: 4.38 (+0.27), XBI: 51.94 (+0.22), IBB: 263.13 (-1.11), TWI: 5.84 (+0.06)
Stocks Charged Up; Canada Dumps Its Gold - Bezek's Daily Briefing
Ian Bezek - at Seeking Alpha - Fri Mar 04, 4:25AM CST
USO: 9.65 (+0.40), VRX: 61.31 (-3.58), UNG: 5.93 (+0.14), XBI: 51.94 (+0.22), UUP: 25.25 (-0.07), SPY: 200.43 (+0.65), LNCO: 0.75 (+0.35), CRC: 1.76 (+0.57), SUNE: 1.78 (+0.26), GLD: 120.54 (-0.19), GOL: 8.52 (-1.56), CAT: 72.84 (+1.09), LINE: 1.00 (+0.41), XLE: 60.96 (+0.58)
SPDR S&P Biotech ETF Set to Possibly Pullback After Yesterday's Rally of 4.16%
Comtex SmarTrend(R) - Wed Mar 02, 6:27PM CST
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $50.00 to a high of $52.41. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $50.34 on volume of 8.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 51.94 (+0.22)
Portola Reports Q4, Updates Business Plans: Analysis Of This High-Risk Play
DoctoRx - at Seeking Alpha - Wed Mar 02, 2:28PM CST
JNJ: 106.50 (-0.15), PTLA: 29.71 (-1.04), XBI: 51.94 (+0.22), PFE: 29.71 (-0.18), MRK: 52.08 (-0.02), AMGN: 145.98 (+0.14), SNY: 39.81 (+0.19), REGN: 403.82 (+1.88)
Generic ETF in Focus as Biotech Lose Charm
Zacks Equity Research - ZACKS - Wed Feb 17, 6:59AM CST
With biotech sector caught in a nasty web of lingering headwinds, this generic ETF invites attention.
AGN: 288.67 (-0.95), JNJ: 106.50 (-0.15), GNRX: 24.10 (unch), AZN: 28.87 (+0.13), PFE: 29.71 (-0.18), XBI: 51.94 (+0.22), AMGN: 145.98 (+0.14), MYL: 44.78 (-0.95), IBB: 263.13 (-1.11), TEVA: 55.62 (+0.02), GSK: 39.14 (-0.04), NVS: 72.20 (-0.75)
Shares of XBI Down 29.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 09, 6:12PM CST
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on January 6th, 2016 at $64.83. In approximately 1 month, SPDR S&P Biotech ETF has returned 29.22% as of today's recent price of $45.88.
XBI: 51.94 (+0.22)
Why Keryx Biopharmaceuticals Inc. Plunged 26% in January
Brian Feroldi, The Motley Fool - Motley Fool - Tue Feb 09, 4:46PM CST
What: Shares of Keryx Biopharmaceuticals , a renal disease-focused biopharmaceutical company, dropped more than 26% in the month of January, according to data from S&P Global Market Intelligence . So what: There wasn't any news released...
XBI: 51.94 (+0.22), KERX: 5.18 (+0.10)
SPDR S&P Biotech ETF Set to Possibly Rebound After Yesterday's Selloff of 5.53%
Comtex SmarTrend(R) - Mon Feb 08, 6:28PM CST
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $45.08 to a high of $47.34. Yesterday, the shares fell 5.5%, which took the trading range below the 3-day low of $46.86 on volume of 8.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 51.94 (+0.22)
Why Share of Novavax Inc Dropped 34% in January
Brian Feroldi, The Motley Fool - Motley Fool - Sat Feb 06, 7:06AM CST
What: The shares of Novavax , a clinical-stage biotechnology company focused on vaccines, had a January to forget, as shares shed 34% of their value during the month, according to data from S&P Capital IQ . The company wasn't alone in...
NVAX: 4.86 (+0.07), XBI: 51.94 (+0.22)
3 Biotech ETFs With Bear-Killing Magic
at The Street - Wed Feb 03, 9:17AM CST
The time is ripe for these three biotechnology exchange-traded funds, which are posting robust double-digit gains while the broader markets falter.
SBIO: 22.37 (+0.02), XBI: 51.94 (+0.22), IBB: 263.13 (-1.11)
After Yesterday's Decline of 3.58%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Tue Feb 02, 6:14PM CST
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $48.65 to a high of $50.42. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $48.78 on volume of 8.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 51.94 (+0.22)
Why Regeneron Pharmaceuticals Shares Fell 23% in January
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 02, 4:40PM CST
Image source: Regeneron Pharmaceuticals. What: Despite news that the FDA has accepted it and co-developer Sanofi 's application for approval of a key drug last month, shares in Regeneron Pharmaceuticals fell 22.6% in January, according to ...
XBI: 51.94 (+0.22), ABBV: 56.15 (+0.22), SNY: 39.81 (+0.19), REGN: 403.82 (+1.88)
SPDR S&P Biotech ETF Has Returned 23.2% Since SmarTrend Recommendation (XBI)
Comtex SmarTrend(R) - Tue Feb 02, 3:22PM CST
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on January 6th, 2016 at $64.83. In approximately 4 weeks, SPDR S&P Biotech ETF has returned 23.16% as of today's recent price of $49.81.
XBI: 51.94 (+0.22)
SPDR S&P Biotech ETF Shares Down 23.2% Since SmarTrend's Sell Call (XBI)
Comtex SmarTrend(R) - Tue Feb 02, 2:11PM CST
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on January 6th, 2016 at $64.83. In approximately 4 weeks, SPDR S&P Biotech ETF has returned 23.16% as of today's recent price of $49.81.
XBI: 51.94 (+0.22)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P Biotech ETF, ALPS Medical Breakthroughs ETF and BioShares Biotechnology Clinical Trials Fund
Zacks Equity Research - Zacks Investment Research - Tue Feb 02, 8:30AM CST
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P Biotech ETF, ALPS Medical Breakthroughs ETF and BioShares Biotechnology Clinical Trials Fund
BBC: 19.08 (+0.02), SBIO: 22.37 (+0.02), XBI: 51.94 (+0.22), IBB: 263.13 (-1.11)
Biotech ETFs Hit 52-Week Lows: Time to Buy?
Sweta Killa - Zacks Investment Research - Mon Feb 01, 8:30AM CST
While investors may want to consider staying on the sidelines given the bearish trend, risk-tolerant long-term investors could consider this slump a buying opportunity.
AGN: 288.67 (-0.95), BIIB: 263.94 (-4.70), BBC: 19.08 (+0.02), SBIO: 22.37 (+0.02), MRK: 52.08 (-0.02), PFE: 29.71 (-0.18), XBI: 51.94 (+0.22), AMGN: 145.98 (+0.14), IBB: 263.13 (-1.11), NVS: 72.20 (-0.75)
Last Week's Best Healthcare ETF
Brian Feroldi, The Motley Fool - Motley Fool - Sat Mar 05, 1:00PM CST
IMAGE BY TBIT VIA PIXABAY. It was another good week to be a healthcare-focused investor. as many of the most popular exchange-traded funds that concentrate on the sector continued to recover from their dreadful start to the year. Several of these...
MDVN: 40.44 (+2.24), ZIOP: 8.95 (-0.64), XBI: 51.94 (+0.22)
So Many Topics, So Few Columns
at The Street - Sat Mar 05, 11:00AM CST
In response to reader input, here's what to look for from me.
XBI: 51.94 (+0.22), IBB: 263.13 (-1.11), BAC: 13.54 (+0.04), GDX: 19.71 (-0.11)
Trader's Notebook: Is It Biotech's Turn to Outperform?
at The Street - Fri Mar 04, 8:00AM CST
The biotechnology sector has lagged horribly.
VALE: 4.38 (+0.27), XBI: 51.94 (+0.22), IBB: 263.13 (-1.11), TWI: 5.84 (+0.06)
Stocks Charged Up; Canada Dumps Its Gold - Bezek's Daily Briefing
Ian Bezek - at Seeking Alpha - Fri Mar 04, 4:25AM CST
USO: 9.65 (+0.40), VRX: 61.31 (-3.58), UNG: 5.93 (+0.14), XBI: 51.94 (+0.22), UUP: 25.25 (-0.07), SPY: 200.43 (+0.65), LNCO: 0.75 (+0.35), CRC: 1.76 (+0.57), SUNE: 1.78 (+0.26), GLD: 120.54 (-0.19), GOL: 8.52 (-1.56), CAT: 72.84 (+1.09), LINE: 1.00 (+0.41), XLE: 60.96 (+0.58)
SPDR S&P Biotech ETF Set to Possibly Pullback After Yesterday's Rally of 4.16%
Comtex SmarTrend(R) - Wed Mar 02, 6:27PM CST
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $50.00 to a high of $52.41. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $50.34 on volume of 8.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 51.94 (+0.22)
Portola Reports Q4, Updates Business Plans: Analysis Of This High-Risk Play
DoctoRx - at Seeking Alpha - Wed Mar 02, 2:28PM CST
JNJ: 106.50 (-0.15), PTLA: 29.71 (-1.04), XBI: 51.94 (+0.22), PFE: 29.71 (-0.18), MRK: 52.08 (-0.02), AMGN: 145.98 (+0.14), SNY: 39.81 (+0.19), REGN: 403.82 (+1.88)
Generic ETF in Focus as Biotech Lose Charm
Zacks Equity Research - ZACKS - Wed Feb 17, 6:59AM CST
With biotech sector caught in a nasty web of lingering headwinds, this generic ETF invites attention.
AGN: 288.67 (-0.95), JNJ: 106.50 (-0.15), GNRX: 24.10 (unch), AZN: 28.87 (+0.13), PFE: 29.71 (-0.18), XBI: 51.94 (+0.22), AMGN: 145.98 (+0.14), MYL: 44.78 (-0.95), IBB: 263.13 (-1.11), TEVA: 55.62 (+0.02), GSK: 39.14 (-0.04), NVS: 72.20 (-0.75)
Shares of XBI Down 29.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 09, 6:12PM CST
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on January 6th, 2016 at $64.83. In approximately 1 month, SPDR S&P Biotech ETF has returned 29.22% as of today's recent price of $45.88.
XBI: 51.94 (+0.22)
Why Keryx Biopharmaceuticals Inc. Plunged 26% in January
Brian Feroldi, The Motley Fool - Motley Fool - Tue Feb 09, 4:46PM CST
What: Shares of Keryx Biopharmaceuticals , a renal disease-focused biopharmaceutical company, dropped more than 26% in the month of January, according to data from S&P Global Market Intelligence . So what: There wasn't any news released...
XBI: 51.94 (+0.22), KERX: 5.18 (+0.10)
SPDR S&P Biotech ETF Set to Possibly Rebound After Yesterday's Selloff of 5.53%
Comtex SmarTrend(R) - Mon Feb 08, 6:28PM CST
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $45.08 to a high of $47.34. Yesterday, the shares fell 5.5%, which took the trading range below the 3-day low of $46.86 on volume of 8.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 51.94 (+0.22)
Why Share of Novavax Inc Dropped 34% in January
Brian Feroldi, The Motley Fool - Motley Fool - Sat Feb 06, 7:06AM CST
What: The shares of Novavax , a clinical-stage biotechnology company focused on vaccines, had a January to forget, as shares shed 34% of their value during the month, according to data from S&P Capital IQ . The company wasn't alone in...
NVAX: 4.86 (+0.07), XBI: 51.94 (+0.22)
3 Biotech ETFs With Bear-Killing Magic
at The Street - Wed Feb 03, 9:17AM CST
The time is ripe for these three biotechnology exchange-traded funds, which are posting robust double-digit gains while the broader markets falter.
SBIO: 22.37 (+0.02), XBI: 51.94 (+0.22), IBB: 263.13 (-1.11)
After Yesterday's Decline of 3.58%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Tue Feb 02, 6:14PM CST
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $48.65 to a high of $50.42. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of $48.78 on volume of 8.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 51.94 (+0.22)
Why Regeneron Pharmaceuticals Shares Fell 23% in January
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 02, 4:40PM CST
Image source: Regeneron Pharmaceuticals. What: Despite news that the FDA has accepted it and co-developer Sanofi 's application for approval of a key drug last month, shares in Regeneron Pharmaceuticals fell 22.6% in January, according to ...
XBI: 51.94 (+0.22), ABBV: 56.15 (+0.22), SNY: 39.81 (+0.19), REGN: 403.82 (+1.88)
SPDR S&P Biotech ETF Has Returned 23.2% Since SmarTrend Recommendation (XBI)
Comtex SmarTrend(R) - Tue Feb 02, 3:22PM CST
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on January 6th, 2016 at $64.83. In approximately 4 weeks, SPDR S&P Biotech ETF has returned 23.16% as of today's recent price of $49.81.
XBI: 51.94 (+0.22)
SPDR S&P Biotech ETF Shares Down 23.2% Since SmarTrend's Sell Call (XBI)
Comtex SmarTrend(R) - Tue Feb 02, 2:11PM CST
SmarTrend identified a Downtrend for SPDR S&P Biotech ETF (AMEX:XBI) on January 6th, 2016 at $64.83. In approximately 4 weeks, SPDR S&P Biotech ETF has returned 23.16% as of today's recent price of $49.81.
XBI: 51.94 (+0.22)
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P Biotech ETF, ALPS Medical Breakthroughs ETF and BioShares Biotechnology Clinical Trials Fund
Zacks Equity Research - Zacks Investment Research - Tue Feb 02, 8:30AM CST
The Zacks Analyst Blog Highlights: iShares Nasdaq Biotechnology ETF, SPDR S&P Biotech ETF, ALPS Medical Breakthroughs ETF and BioShares Biotechnology Clinical Trials Fund
BBC: 19.08 (+0.02), SBIO: 22.37 (+0.02), XBI: 51.94 (+0.22), IBB: 263.13 (-1.11)
Biotech ETFs Hit 52-Week Lows: Time to Buy?
Sweta Killa - Zacks Investment Research - Mon Feb 01, 8:30AM CST
While investors may want to consider staying on the sidelines given the bearish trend, risk-tolerant long-term investors could consider this slump a buying opportunity.
AGN: 288.67 (-0.95), BIIB: 263.94 (-4.70), BBC: 19.08 (+0.02), SBIO: 22.37 (+0.02), MRK: 52.08 (-0.02), PFE: 29.71 (-0.18), XBI: 51.94 (+0.22), AMGN: 145.98 (+0.14), IBB: 263.13 (-1.11), NVS: 72.20 (-0.75)
(0)
(0)